Every engagement looks different, but the goal is always the same: help clients expand patient access and protect product value. The case studies below explore how we’ve helped life sciences leaders make faster, smarter decisions when it mattered most.
.png)
Developed a stakeholder-validated payer value framework, evidence generation roadmap, and decision-support tools to align scientific messaging with future market access priorities for a Phase III oncology therapy.
.png)
Assessed the value and limitations of existing real-world evidence and developed an adaptable Medicare claims protocol to guide future research, publications, and value demonstration.
.png)
Developed a living global value resource that standardized value communication across markets while giving regional teams the flexibility to tailor evidence and messaging to local access needs.
.png)
Built a cohesive portfolio-level value narrative that aligned leadership, clarified the portfolio’s strategic role, and identified priorities for future evidence and market access planning.
.png)
Facilitated a leadership strategy initiative that aligned a top five pharmaceutical company's Global RWE function on its mission, strategic value, and future direction, creating a shared vision to guide enterprise-wide evidence generation.
.png)
Developed a unified market access strategy and value narrative that aligned cross-functional teams, prioritized evidence investments, and strengthened adoption planning for an innovative oncology technology.
Defined the value landscape and built a clear, evidence-based narrative to help communicate clinical and economic impact to decision-makers.
.png)
Clarified and validated a U.S.-specific payer value story, then translated it into field-ready tools that strengthened payer conversations and accelerated adoption after a key regulatory milestone.
.png)
Designed a scalable patient and HCP engagement strategy that improved recruitment, strengthened global coordination, and supported pre-launch research and access planning for a rare disease therapy.
.png)
Delivered a rapid assessment of CPT feasibility and reimbursement pathways to guide evidence generation and early U.S. commercial planning for a pre-launch ENT imaging device.
.png)
Defined and communicated a patient-reported outcomes strategy that strengthened regulatory positioning and translated trial outcomes into a clear, credible narrative for investors.
.png)
Pressure-tested and refined a rare disease payer value story across Europe, aligning country-specific access expectations and defining evidence priorities to strengthen HTA and reimbursement readiness.
.png)
Synthesized clinical and real-world evidence into a structured value narrative that supported CMS engagement and guided U.S. coverage expansion for an established cardiovascular intervention.
.png)
Developed coordinated payer and guideline communication tools that enabled rapid AMCP readiness, favorable NCCN inclusion, and accelerated adoption at launch.
.png)
Aligned HEOR and modeling strategy with country-specific HTA expectations to reduce access risk, strengthen submissions, and guide launch sequencing ahead of a rare disease launch.
.png)
Clarified payer evidence expectations and strengthened the pre-launch value narrative for a rare disease therapy facing heightened scrutiny around surrogate endpoints.
Designed and executed a multi-study evidence program to define disease burden, document patient and provider perspectives, and strengthen payer coverage discussions ahead of launch.
.png)
Partnered across evidence generation, value communication, and payer strategy to support guideline inclusion and broad U.S. coverage at launch for a rare oncology therapy.
Defined a clear value and reimbursement strategy for a newly FDA-cleared diagnostic, supporting coding, pricing, and early commercialization, including CMS discussions and investor momentum.
.png)
Developed a payer-focused value narrative and budget impact model that supported CMS discussions and helped secure national outpatient coverage for a novel treatment modality.
.png)
Developed a launch-ready U.S. reimbursement and market access strategy to clarify access risk, define evidence priorities, and support adoption of a novel PET diagnostic radiotracer.
.png)
Tested and refined value propositions directly with U.S. payers to inform pricing, evidence priorities, and market access strategy ahead of launch.
.png)
Built an evidence-based payer value case to support U.S. coverage discussions and accelerate access for an innovative endoscopic obesity treatment.
.png)
Developed and validated a hospital-level economic value case to help a large medtech communicate budget impact and accelerate adoption of a novel medication delivery technology.
.png)
Defined an early payer value story and evidence roadmap to prioritize Phase III data generation and strengthen market access readiness ahead of launch.
.png)
Helped a mid-size medtech articulate the environmental impact of its radiology portfolio to strengthen differentiation and engage clinical and access stakeholders.
.png)
Helped a large diagnostics company prioritize evidence generation to strengthen its value narrative and support adoption amid increasing payer scrutiny.
.png)
Rapidly assessed the surgical complications landscape to help a large medtech company prioritize unmet needs and focus its early-stage innovation pipeline.
Supported a private equity investment decision by assessing EU reimbursement dynamics, pricing outlook, and volume trends for a diagnostics portfolio across key markets.
Supported a mid-size biotech in responding to emerging real-world evidence that favored a competitor by clarifying methodological limitations, shaping the evidence narrative, and protecting long-term access and positioning.
Centralized local access insights into a single, usable system to reduce duplication, accelerate launch readiness, and enable consistent payer strategies across markets.
.png)
Developed a forward-looking value framework to help a biotech align clinical development and evidence generation with evolving payer expectations in obesity.
.png)
Clarified patient segmentation and value drivers to reduce early uncertainty and guide product planning and market access strategy.
.png)
Built a payer-ready clinical and economic value case to support U.S. coverage discussions and accelerate reimbursement decisions for an innovative medical device.
.png)
Established a clear, evidence-based value narrative to support payer coverage discussions and enable access for a novel cardiac device.
.png)
Clarified and aligned the evidence base across stakeholders to support consistent value communication and accelerate adoption in an insured market.
.png)
Validated a new market opportunity by clarifying patient segmentation, unmet need, and economic dynamics to support early investment and development decisions.
.png)
Developed a clear, evidence-based value narrative to support payer discussions and strengthen coverage decisions across a diagnostic portfolio.
.png)
Validated how decision-makers evaluate new diagnostic tests, clarified what evidence would drive adoption, and informed a focused strategy to support uptake at launch.
.png)
Defined an early value story and evidence generation roadmap to guide clinical, HEOR, and commercial planning for a rare disease therapy under an accelerated timeline.
.png)
Aligned global and local teams to anticipate HTA challenges early, clarify disease burden and value expectations, and reduce reimbursement risk ahead of launch in HTA-driven markets.
Tested and refined value propositions directly with U.S. payers to inform pricing, evidence priorities, and market access strategy ahead of launch.
Validated how decision-makers evaluate new diagnostic tests, clarified what evidence would drive adoption, and informed a focused strategy to support uptake at launch.
Clarified and validated a U.S.-specific payer value story, then translated it into field-ready tools that strengthened payer conversations and accelerated adoption after a key regulatory milestone.
Defined and communicated a patient-reported outcomes strategy that strengthened regulatory positioning and translated trial outcomes into a clear, credible narrative for investors.
Pressure-tested and refined a rare disease payer value story across Europe, aligning country-specific access expectations and defining evidence priorities to strengthen HTA and reimbursement readiness.
Developed coordinated payer and guideline communication tools that enabled rapid AMCP readiness, favorable NCCN inclusion, and accelerated adoption at launch.
Aligned HEOR and modeling strategy with country-specific HTA expectations to reduce access risk, strengthen submissions, and guide launch sequencing ahead of a rare disease launch.
Clarified payer evidence expectations and strengthened the pre-launch value narrative for a rare disease therapy facing heightened scrutiny around surrogate endpoints.
Designed and executed a multi-study evidence program to define disease burden, document patient and provider perspectives, and strengthen payer coverage discussions ahead of launch.
Partnered across evidence generation, value communication, and payer strategy to support guideline inclusion and broad U.S. coverage at launch for a rare oncology therapy.
Defined an early payer value story and evidence roadmap to prioritize Phase III data generation and strengthen market access readiness ahead of launch.
Supported a mid-size biotech in responding to emerging real-world evidence that favored a competitor by clarifying methodological limitations, shaping the evidence narrative, and protecting long-term access and positioning.
Developed a forward-looking value framework to help a biotech align clinical development and evidence generation with evolving payer expectations in obesity.
Defined an early value story and evidence generation roadmap to guide clinical, HEOR, and commercial planning for a rare disease therapy under an accelerated timeline.
Defined an early value story and evidence generation roadmap to guide clinical, HEOR, and commercial planning for a rare disease therapy under an accelerated timeline.
Developed a living global value resource that standardized value communication across markets while giving regional teams the flexibility to tailor evidence and messaging to local access needs.
Built a payer-ready clinical and economic value case to support U.S. coverage discussions and accelerate reimbursement decisions for an innovative medical device.
Established a clear, evidence-based value narrative to support payer coverage discussions and enable access for a novel cardiac device.
Clarified and aligned the evidence base across stakeholders to support consistent value communication and accelerate adoption in an insured market.
Developed a stakeholder-validated payer value framework, evidence generation roadmap, and decision-support tools to align scientific messaging with future market access priorities for a Phase III oncology therapy.
Assessed the value and limitations of existing real-world evidence and developed an adaptable Medicare claims protocol to guide future research, publications, and value demonstration.
Facilitated a leadership strategy initiative that aligned a top five pharmaceutical company's Global RWE function on its mission, strategic value, and future direction, creating a shared vision to guide enterprise-wide evidence generation.
Developed a unified market access strategy and value narrative that aligned cross-functional teams, prioritized evidence investments, and strengthened adoption planning for an innovative oncology technology.
Aligned HEOR and modeling strategy with country-specific HTA expectations to reduce access risk, strengthen submissions, and guide launch sequencing ahead of a rare disease launch.
Designed and executed a multi-study evidence program to define disease burden, document patient and provider perspectives, and strengthen payer coverage discussions ahead of launch.
Built an evidence-based payer value case to support U.S. coverage discussions and accelerate access for an innovative endoscopic obesity treatment.
Developed and validated a hospital-level economic value case to help a large medtech communicate budget impact and accelerate adoption of a novel medication delivery technology.
Helped a large diagnostics company prioritize evidence generation to strengthen its value narrative and support adoption amid increasing payer scrutiny.
Supported a private equity investment decision by assessing EU reimbursement dynamics, pricing outlook, and volume trends for a diagnostics portfolio across key markets.
Supported a mid-size biotech in responding to emerging real-world evidence that favored a competitor by clarifying methodological limitations, shaping the evidence narrative, and protecting long-term access and positioning.
Clarified patient segmentation and value drivers to reduce early uncertainty and guide product planning and market access strategy.
Built a payer-ready clinical and economic value case to support U.S. coverage discussions and accelerate reimbursement decisions for an innovative medical device.
Established a clear, evidence-based value narrative to support payer coverage discussions and enable access for a novel cardiac device.
Validated a new market opportunity by clarifying patient segmentation, unmet need, and economic dynamics to support early investment and development decisions.
Validated how decision-makers evaluate new diagnostic tests, clarified what evidence would drive adoption, and informed a focused strategy to support uptake at launch.
Defined an early value story and evidence generation roadmap to guide clinical, HEOR, and commercial planning for a rare disease therapy under an accelerated timeline.
Pressure-tested and refined a rare disease payer value story across Europe, aligning country-specific access expectations and defining evidence priorities to strengthen HTA and reimbursement readiness.
Aligned HEOR and modeling strategy with country-specific HTA expectations to reduce access risk, strengthen submissions, and guide launch sequencing ahead of a rare disease launch.
Aligned global and local teams to anticipate HTA challenges early, clarify disease burden and value expectations, and reduce reimbursement risk ahead of launch in HTA-driven markets.
Built a payer-ready clinical and economic value case to support U.S. coverage discussions and accelerate reimbursement decisions for an innovative medical device.
Clarified patient segmentation and value drivers to reduce early uncertainty and guide product planning and market access strategy.
Validated a new market opportunity by clarifying patient segmentation, unmet need, and economic dynamics to support early investment and development decisions.
Developed a stakeholder-validated payer value framework, evidence generation roadmap, and decision-support tools to align scientific messaging with future market access priorities for a Phase III oncology therapy.
Assessed the value and limitations of existing real-world evidence and developed an adaptable Medicare claims protocol to guide future research, publications, and value demonstration.
Developed a living global value resource that standardized value communication across markets while giving regional teams the flexibility to tailor evidence and messaging to local access needs.
Built a cohesive portfolio-level value narrative that aligned leadership, clarified the portfolio’s strategic role, and identified priorities for future evidence and market access planning.
Facilitated a leadership strategy initiative that aligned a top five pharmaceutical company's Global RWE function on its mission, strategic value, and future direction, creating a shared vision to guide enterprise-wide evidence generation.
Developed a unified market access strategy and value narrative that aligned cross-functional teams, prioritized evidence investments, and strengthened adoption planning for an innovative oncology technology.
Defined the value landscape and built a clear, evidence-based narrative to help communicate clinical and economic impact to decision-makers.
Clarified and validated a U.S.-specific payer value story, then translated it into field-ready tools that strengthened payer conversations and accelerated adoption after a key regulatory milestone.
Designed a scalable patient and HCP engagement strategy that improved recruitment, strengthened global coordination, and supported pre-launch research and access planning for a rare disease therapy.
Delivered a rapid assessment of CPT feasibility and reimbursement pathways to guide evidence generation and early U.S. commercial planning for a pre-launch ENT imaging device.
Defined and communicated a patient-reported outcomes strategy that strengthened regulatory positioning and translated trial outcomes into a clear, credible narrative for investors.
Pressure-tested and refined a rare disease payer value story across Europe, aligning country-specific access expectations and defining evidence priorities to strengthen HTA and reimbursement readiness.
Synthesized clinical and real-world evidence into a structured value narrative that supported CMS engagement and guided U.S. coverage expansion for an established cardiovascular intervention.
Developed coordinated payer and guideline communication tools that enabled rapid AMCP readiness, favorable NCCN inclusion, and accelerated adoption at launch.
Aligned HEOR and modeling strategy with country-specific HTA expectations to reduce access risk, strengthen submissions, and guide launch sequencing ahead of a rare disease launch.
Clarified payer evidence expectations and strengthened the pre-launch value narrative for a rare disease therapy facing heightened scrutiny around surrogate endpoints.
Designed and executed a multi-study evidence program to define disease burden, document patient and provider perspectives, and strengthen payer coverage discussions ahead of launch.
Partnered across evidence generation, value communication, and payer strategy to support guideline inclusion and broad U.S. coverage at launch for a rare oncology therapy.
Defined a clear value and reimbursement strategy for a newly FDA-cleared diagnostic, supporting coding, pricing, and early commercialization, including CMS discussions and investor momentum.
Developed a payer-focused value narrative and budget impact model that supported CMS discussions and helped secure national outpatient coverage for a novel treatment modality.
Developed a launch-ready U.S. reimbursement and market access strategy to clarify access risk, define evidence priorities, and support adoption of a novel PET diagnostic radiotracer.
Tested and refined value propositions directly with U.S. payers to inform pricing, evidence priorities, and market access strategy ahead of launch.
Built an evidence-based payer value case to support U.S. coverage discussions and accelerate access for an innovative endoscopic obesity treatment.
Developed and validated a hospital-level economic value case to help a large medtech communicate budget impact and accelerate adoption of a novel medication delivery technology.
Defined an early payer value story and evidence roadmap to prioritize Phase III data generation and strengthen market access readiness ahead of launch.
Helped a mid-size medtech articulate the environmental impact of its radiology portfolio to strengthen differentiation and engage clinical and access stakeholders.
Helped a large diagnostics company prioritize evidence generation to strengthen its value narrative and support adoption amid increasing payer scrutiny.
Rapidly assessed the surgical complications landscape to help a large medtech company prioritize unmet needs and focus its early-stage innovation pipeline.
Centralized local access insights into a single, usable system to reduce duplication, accelerate launch readiness, and enable consistent payer strategies across markets.
Developed a forward-looking value framework to help a biotech align clinical development and evidence generation with evolving payer expectations in obesity.
Built a payer-ready clinical and economic value case to support U.S. coverage discussions and accelerate reimbursement decisions for an innovative medical device.
Established a clear, evidence-based value narrative to support payer coverage discussions and enable access for a novel cardiac device.
Clarified and aligned the evidence base across stakeholders to support consistent value communication and accelerate adoption in an insured market.
Developed a clear, evidence-based value narrative to support payer discussions and strengthen coverage decisions across a diagnostic portfolio.
Validated how decision-makers evaluate new diagnostic tests, clarified what evidence would drive adoption, and informed a focused strategy to support uptake at launch.
Defined an early value story and evidence generation roadmap to guide clinical, HEOR, and commercial planning for a rare disease therapy under an accelerated timeline.
Aligned global and local teams to anticipate HTA challenges early, clarify disease burden and value expectations, and reduce reimbursement risk ahead of launch in HTA-driven markets.
Clarified and validated a U.S.-specific payer value story, then translated it into field-ready tools that strengthened payer conversations and accelerated adoption after a key regulatory milestone.
Designed a scalable patient and HCP engagement strategy that improved recruitment, strengthened global coordination, and supported pre-launch research and access planning for a rare disease therapy.
Delivered a rapid assessment of CPT feasibility and reimbursement pathways to guide evidence generation and early U.S. commercial planning for a pre-launch ENT imaging device.
Defined and communicated a patient-reported outcomes strategy that strengthened regulatory positioning and translated trial outcomes into a clear, credible narrative for investors.
Pressure-tested and refined a rare disease payer value story across Europe, aligning country-specific access expectations and defining evidence priorities to strengthen HTA and reimbursement readiness.
Synthesized clinical and real-world evidence into a structured value narrative that supported CMS engagement and guided U.S. coverage expansion for an established cardiovascular intervention.
Developed coordinated payer and guideline communication tools that enabled rapid AMCP readiness, favorable NCCN inclusion, and accelerated adoption at launch.
Clarified payer evidence expectations and strengthened the pre-launch value narrative for a rare disease therapy facing heightened scrutiny around surrogate endpoints.
Partnered across evidence generation, value communication, and payer strategy to support guideline inclusion and broad U.S. coverage at launch for a rare oncology therapy.
Defined a clear value and reimbursement strategy for a newly FDA-cleared diagnostic, supporting coding, pricing, and early commercialization, including CMS discussions and investor momentum.
Developed a payer-focused value narrative and budget impact model that supported CMS discussions and helped secure national outpatient coverage for a novel treatment modality.
Developed a launch-ready U.S. reimbursement and market access strategy to clarify access risk, define evidence priorities, and support adoption of a novel PET diagnostic radiotracer.
Tested and refined value propositions directly with U.S. payers to inform pricing, evidence priorities, and market access strategy ahead of launch.
Built an evidence-based payer value case to support U.S. coverage discussions and accelerate access for an innovative endoscopic obesity treatment.
Developed and validated a hospital-level economic value case to help a large medtech communicate budget impact and accelerate adoption of a novel medication delivery technology.
Defined an early payer value story and evidence roadmap to prioritize Phase III data generation and strengthen market access readiness ahead of launch.
Helped a mid-size medtech articulate the environmental impact of its radiology portfolio to strengthen differentiation and engage clinical and access stakeholders.
Rapidly assessed the surgical complications landscape to help a large medtech company prioritize unmet needs and focus its early-stage innovation pipeline.
Supported a private equity investment decision by assessing EU reimbursement dynamics, pricing outlook, and volume trends for a diagnostics portfolio across key markets.
Developed a forward-looking value framework to help a biotech align clinical development and evidence generation with evolving payer expectations in obesity.
Clarified patient segmentation and value drivers to reduce early uncertainty and guide product planning and market access strategy.
Built a payer-ready clinical and economic value case to support U.S. coverage discussions and accelerate reimbursement decisions for an innovative medical device.
Validated a new market opportunity by clarifying patient segmentation, unmet need, and economic dynamics to support early investment and development decisions.
Developed a clear, evidence-based value narrative to support payer discussions and strengthen coverage decisions across a diagnostic portfolio.
Validated how decision-makers evaluate new diagnostic tests, clarified what evidence would drive adoption, and informed a focused strategy to support uptake at launch.
Defined the value landscape and built a clear, evidence-based narrative to help communicate clinical and economic impact to decision-makers.
Delivered a rapid assessment of CPT feasibility and reimbursement pathways to guide evidence generation and early U.S. commercial planning for a pre-launch ENT imaging device.
Synthesized clinical and real-world evidence into a structured value narrative that supported CMS engagement and guided U.S. coverage expansion for an established cardiovascular intervention.
Defined a clear value and reimbursement strategy for a newly FDA-cleared diagnostic, supporting coding, pricing, and early commercialization, including CMS discussions and investor momentum.
Developed a payer-focused value narrative and budget impact model that supported CMS discussions and helped secure national outpatient coverage for a novel treatment modality.
Developed a launch-ready U.S. reimbursement and market access strategy to clarify access risk, define evidence priorities, and support adoption of a novel PET diagnostic radiotracer.
Built an evidence-based payer value case to support U.S. coverage discussions and accelerate access for an innovative endoscopic obesity treatment.
Developed and validated a hospital-level economic value case to help a large medtech communicate budget impact and accelerate adoption of a novel medication delivery technology.
Helped a mid-size medtech articulate the environmental impact of its radiology portfolio to strengthen differentiation and engage clinical and access stakeholders.
Helped a large diagnostics company prioritize evidence generation to strengthen its value narrative and support adoption amid increasing payer scrutiny.
Rapidly assessed the surgical complications landscape to help a large medtech company prioritize unmet needs and focus its early-stage innovation pipeline.
Supported a private equity investment decision by assessing EU reimbursement dynamics, pricing outlook, and volume trends for a diagnostics portfolio across key markets.
Clarified patient segmentation and value drivers to reduce early uncertainty and guide product planning and market access strategy.
Built a payer-ready clinical and economic value case to support U.S. coverage discussions and accelerate reimbursement decisions for an innovative medical device.
Established a clear, evidence-based value narrative to support payer coverage discussions and enable access for a novel cardiac device.
Clarified and aligned the evidence base across stakeholders to support consistent value communication and accelerate adoption in an insured market.
Validated a new market opportunity by clarifying patient segmentation, unmet need, and economic dynamics to support early investment and development decisions.
Developed a clear, evidence-based value narrative to support payer discussions and strengthen coverage decisions across a diagnostic portfolio.
Validated how decision-makers evaluate new diagnostic tests, clarified what evidence would drive adoption, and informed a focused strategy to support uptake at launch.
Designed a scalable patient and HCP engagement strategy that improved recruitment, strengthened global coordination, and supported pre-launch research and access planning for a rare disease therapy.
Developed a launch-ready U.S. reimbursement and market access strategy to clarify access risk, define evidence priorities, and support adoption of a novel PET diagnostic radiotracer.
Tested and refined value propositions directly with U.S. payers to inform pricing, evidence priorities, and market access strategy ahead of launch.
Centralized local access insights into a single, usable system to reduce duplication, accelerate launch readiness, and enable consistent payer strategies across markets.
Aligned global and local teams to anticipate HTA challenges early, clarify disease burden and value expectations, and reduce reimbursement risk ahead of launch in HTA-driven markets.
Developed a stakeholder-validated payer value framework, evidence generation roadmap, and decision-support tools to align scientific messaging with future market access priorities for a Phase III oncology therapy.
Clarified and validated a U.S.-specific payer value story, then translated it into field-ready tools that strengthened payer conversations and accelerated adoption after a key regulatory milestone.
Defined and communicated a patient-reported outcomes strategy that strengthened regulatory positioning and translated trial outcomes into a clear, credible narrative for investors.
Pressure-tested and refined a rare disease payer value story across Europe, aligning country-specific access expectations and defining evidence priorities to strengthen HTA and reimbursement readiness.
Synthesized clinical and real-world evidence into a structured value narrative that supported CMS engagement and guided U.S. coverage expansion for an established cardiovascular intervention.
Clarified payer evidence expectations and strengthened the pre-launch value narrative for a rare disease therapy facing heightened scrutiny around surrogate endpoints.
Defined a clear value and reimbursement strategy for a newly FDA-cleared diagnostic, supporting coding, pricing, and early commercialization, including CMS discussions and investor momentum.
Tested and refined value propositions directly with U.S. payers to inform pricing, evidence priorities, and market access strategy ahead of launch.
Developed and validated a hospital-level economic value case to help a large medtech communicate budget impact and accelerate adoption of a novel medication delivery technology.
Helped a large diagnostics company prioritize evidence generation to strengthen its value narrative and support adoption amid increasing payer scrutiny.
Supported a private equity investment decision by assessing EU reimbursement dynamics, pricing outlook, and volume trends for a diagnostics portfolio across key markets.
Developed a forward-looking value framework to help a biotech align clinical development and evidence generation with evolving payer expectations in obesity.
Clarified patient segmentation and value drivers to reduce early uncertainty and guide product planning and market access strategy.
Validated a new market opportunity by clarifying patient segmentation, unmet need, and economic dynamics to support early investment and development decisions.
Developed a clear, evidence-based value narrative to support payer discussions and strengthen coverage decisions across a diagnostic portfolio.
Validated how decision-makers evaluate new diagnostic tests, clarified what evidence would drive adoption, and informed a focused strategy to support uptake at launch.
Aligned global and local teams to anticipate HTA challenges early, clarify disease burden and value expectations, and reduce reimbursement risk ahead of launch in HTA-driven markets.
Developed a stakeholder-validated payer value framework, evidence generation roadmap, and decision-support tools to align scientific messaging with future market access priorities for a Phase III oncology therapy.
Assessed the value and limitations of existing real-world evidence and developed an adaptable Medicare claims protocol to guide future research, publications, and value demonstration.
Built a cohesive portfolio-level value narrative that aligned leadership, clarified the portfolio’s strategic role, and identified priorities for future evidence and market access planning.
Facilitated a leadership strategy initiative that aligned a top five pharmaceutical company's Global RWE function on its mission, strategic value, and future direction, creating a shared vision to guide enterprise-wide evidence generation.
Developed a unified market access strategy and value narrative that aligned cross-functional teams, prioritized evidence investments, and strengthened adoption planning for an innovative oncology technology.
Designed a scalable patient and HCP engagement strategy that improved recruitment, strengthened global coordination, and supported pre-launch research and access planning for a rare disease therapy.
Synthesized clinical and real-world evidence into a structured value narrative that supported CMS engagement and guided U.S. coverage expansion for an established cardiovascular intervention.
Developed coordinated payer and guideline communication tools that enabled rapid AMCP readiness, favorable NCCN inclusion, and accelerated adoption at launch.
Aligned HEOR and modeling strategy with country-specific HTA expectations to reduce access risk, strengthen submissions, and guide launch sequencing ahead of a rare disease launch.
Partnered across evidence generation, value communication, and payer strategy to support guideline inclusion and broad U.S. coverage at launch for a rare oncology therapy.
Developed a payer-focused value narrative and budget impact model that supported CMS discussions and helped secure national outpatient coverage for a novel treatment modality.
Defined an early payer value story and evidence roadmap to prioritize Phase III data generation and strengthen market access readiness ahead of launch.
Helped a large diagnostics company prioritize evidence generation to strengthen its value narrative and support adoption amid increasing payer scrutiny.
Supported a mid-size biotech in responding to emerging real-world evidence that favored a competitor by clarifying methodological limitations, shaping the evidence narrative, and protecting long-term access and positioning.
Validated a new market opportunity by clarifying patient segmentation, unmet need, and economic dynamics to support early investment and development decisions.
Clarified and validated a U.S.-specific payer value story, then translated it into field-ready tools that strengthened payer conversations and accelerated adoption after a key regulatory milestone.
Designed a scalable patient and HCP engagement strategy that improved recruitment, strengthened global coordination, and supported pre-launch research and access planning for a rare disease therapy.
Aligned HEOR and modeling strategy with country-specific HTA expectations to reduce access risk, strengthen submissions, and guide launch sequencing ahead of a rare disease launch.
Clarified payer evidence expectations and strengthened the pre-launch value narrative for a rare disease therapy facing heightened scrutiny around surrogate endpoints.
Designed and executed a multi-study evidence program to define disease burden, document patient and provider perspectives, and strengthen payer coverage discussions ahead of launch.
Supported a mid-size biotech in responding to emerging real-world evidence that favored a competitor by clarifying methodological limitations, shaping the evidence narrative, and protecting long-term access and positioning.
Defined an early value story and evidence generation roadmap to guide clinical, HEOR, and commercial planning for a rare disease therapy under an accelerated timeline.
Developed a stakeholder-validated payer value framework, evidence generation roadmap, and decision-support tools to align scientific messaging with future market access priorities for a Phase III oncology therapy.
Assessed the value and limitations of existing real-world evidence and developed an adaptable Medicare claims protocol to guide future research, publications, and value demonstration.
Developed a living global value resource that standardized value communication across markets while giving regional teams the flexibility to tailor evidence and messaging to local access needs.
Built a cohesive portfolio-level value narrative that aligned leadership, clarified the portfolio’s strategic role, and identified priorities for future evidence and market access planning.
Facilitated a leadership strategy initiative that aligned a top five pharmaceutical company's Global RWE function on its mission, strategic value, and future direction, creating a shared vision to guide enterprise-wide evidence generation.
Developed a unified market access strategy and value narrative that aligned cross-functional teams, prioritized evidence investments, and strengthened adoption planning for an innovative oncology technology.
Defined the value landscape and built a clear, evidence-based narrative to help communicate clinical and economic impact to decision-makers.
Clarified and validated a U.S.-specific payer value story, then translated it into field-ready tools that strengthened payer conversations and accelerated adoption after a key regulatory milestone.
Designed a scalable patient and HCP engagement strategy that improved recruitment, strengthened global coordination, and supported pre-launch research and access planning for a rare disease therapy.
Delivered a rapid assessment of CPT feasibility and reimbursement pathways to guide evidence generation and early U.S. commercial planning for a pre-launch ENT imaging device.
Defined and communicated a patient-reported outcomes strategy that strengthened regulatory positioning and translated trial outcomes into a clear, credible narrative for investors.
Pressure-tested and refined a rare disease payer value story across Europe, aligning country-specific access expectations and defining evidence priorities to strengthen HTA and reimbursement readiness.
Synthesized clinical and real-world evidence into a structured value narrative that supported CMS engagement and guided U.S. coverage expansion for an established cardiovascular intervention.
Developed coordinated payer and guideline communication tools that enabled rapid AMCP readiness, favorable NCCN inclusion, and accelerated adoption at launch.
Aligned HEOR and modeling strategy with country-specific HTA expectations to reduce access risk, strengthen submissions, and guide launch sequencing ahead of a rare disease launch.
Clarified payer evidence expectations and strengthened the pre-launch value narrative for a rare disease therapy facing heightened scrutiny around surrogate endpoints.
Designed and executed a multi-study evidence program to define disease burden, document patient and provider perspectives, and strengthen payer coverage discussions ahead of launch.
Partnered across evidence generation, value communication, and payer strategy to support guideline inclusion and broad U.S. coverage at launch for a rare oncology therapy.
Defined a clear value and reimbursement strategy for a newly FDA-cleared diagnostic, supporting coding, pricing, and early commercialization, including CMS discussions and investor momentum.
Developed a payer-focused value narrative and budget impact model that supported CMS discussions and helped secure national outpatient coverage for a novel treatment modality.
Tested and refined value propositions directly with U.S. payers to inform pricing, evidence priorities, and market access strategy ahead of launch.
Built an evidence-based payer value case to support U.S. coverage discussions and accelerate access for an innovative endoscopic obesity treatment.
Developed and validated a hospital-level economic value case to help a large medtech communicate budget impact and accelerate adoption of a novel medication delivery technology.
Defined an early payer value story and evidence roadmap to prioritize Phase III data generation and strengthen market access readiness ahead of launch.
Helped a mid-size medtech articulate the environmental impact of its radiology portfolio to strengthen differentiation and engage clinical and access stakeholders.
Helped a large diagnostics company prioritize evidence generation to strengthen its value narrative and support adoption amid increasing payer scrutiny.
Rapidly assessed the surgical complications landscape to help a large medtech company prioritize unmet needs and focus its early-stage innovation pipeline.
Supported a private equity investment decision by assessing EU reimbursement dynamics, pricing outlook, and volume trends for a diagnostics portfolio across key markets.
Centralized local access insights into a single, usable system to reduce duplication, accelerate launch readiness, and enable consistent payer strategies across markets.
Developed a forward-looking value framework to help a biotech align clinical development and evidence generation with evolving payer expectations in obesity.
Clarified patient segmentation and value drivers to reduce early uncertainty and guide product planning and market access strategy.
Built a payer-ready clinical and economic value case to support U.S. coverage discussions and accelerate reimbursement decisions for an innovative medical device.
Established a clear, evidence-based value narrative to support payer coverage discussions and enable access for a novel cardiac device.
Clarified and aligned the evidence base across stakeholders to support consistent value communication and accelerate adoption in an insured market.
Developed a clear, evidence-based value narrative to support payer discussions and strengthen coverage decisions across a diagnostic portfolio.
Validated how decision-makers evaluate new diagnostic tests, clarified what evidence would drive adoption, and informed a focused strategy to support uptake at launch.
Defined an early value story and evidence generation roadmap to guide clinical, HEOR, and commercial planning for a rare disease therapy under an accelerated timeline.
Aligned global and local teams to anticipate HTA challenges early, clarify disease burden and value expectations, and reduce reimbursement risk ahead of launch in HTA-driven markets.